Sumitomo Pharma’s DX

By implementing a data-driven decision-making process, all value chains will make continued efforts to innovate operations and create value

A Data-driven Organization that Propels Itself Autonomously
Digital data is used as a matter of fact

Optimal Use of In-house Technologies Acquired through Strategic Investment（DrugOME / Digital Innovation）

Corporate Departments Orchestrate DX of the Sumitomo Pharma Group

Introduce Advanced Technologies and Techniques(web3.0, metaverse, quantum computers, etc.)

We acquired DrugOME and Digital Innovation, which are healthcare technology platforms, and the talents to utilize them through strategic investments under our Med-term Business Plan 2022, in order to accelerate the Group’s DX efforts. By making full use of these systems, technologies, and talents, and by setting quantitative targets linked to sales and R&D milestones, we will improve the accuracy of drug discovery, shorten the development period, and stably manufacture drugs that are safe and more reliable than ever, so that we will generate innovative pharmaceuticals and healthcare solutions as well as deliver value to a wider range of healthcare professionals, patients and their families.
To contribute to the health and wellbeing of people, we will accelerate our DX efforts by focusing on the creation and enhancement of business value, and promote our “transformation into a data-driven pharmaceutical company” and “new value creation and operational reforms” to achieve sustained growth.

Introduce Advanced Technologies and Techniques